What is GLP-RT?

GLP-RT is a synthetic 39-amino acid peptide that acts as a unimolecular tri-agonist at receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG). This triple mechanism differentiates it from earlier incretin-based compounds.

GLP-1 receptor activation enhances insulin secretion and reduces glucagon output in a glucose-dependent manner, while also promoting satiety and slowing gastric emptying. GIP receptor co-activation potentiates insulin release and has additive effects on body weight reduction. Simultaneous glucagon receptor agonism increases energy expenditure through hepatic and adipose pathways - a mechanism that distinguishes GLP-RT from dual agonists such as GLP-TZ.

The convergence of these three pathways in a single molecule creates a synergistic profile with potential implications for research into obesity, non-alcoholic fatty liver disease (NAFLD/NASH), dyslipidaemia, and type 2 diabetes mellitus.

Product Code

GLP-RT

Receptor Targets

GLP-1R, GIPR, GCGR

Mechanism

Triple Agonist

Molecular Weight

~4,540 Da

Sequence Length

39 Amino Acids

Research Background

Phase 2–style trial data in the literature report remarkable findings for this mechanism class:

Mean body weight reductions of up to 24% over 48 weeks at maximum studied doses - exceeding many dual-agonist and monoagonist comparators in published analyses.
Statistically significant improvements in HbA1c, fasting glucose, and insulin sensitivity markers.
Reductions in triglycerides, LDL-cholesterol, and hepatic fat fraction in participants with metabolic-associated steatotic liver disease.
Consistent improvements in waist circumference and visceral adiposity metrics, suggesting meaningful changes in body composition beyond simple weight loss.
The glucagon receptor component is hypothesised to drive the incremental efficacy beyond dual agonism through enhanced hepatic glucose output regulation and brown adipose tissue thermogenesis.

Research Applications

GLP-RT is being actively investigated for applications including:

Obesity and adiposity research models
Type 2 diabetes and insulin resistance mechanistic studies
Non-alcoholic fatty liver disease (NAFLD / NASH) investigation
Dyslipidaemia and cardiovascular risk marker research
Energy expenditure and thermogenesis mechanistic research

Technical Specifications

Appearance

White Lyophilised Powder

Purity

≥99%

Format

Lyophilised (Freeze-Dried)

Reconstitution

Bacteriostatic Water

Storage (Lyophilised)

−20°C, protected from light

Storage (Reconstituted)

2–8°C, use within 28 days

Shelf Life

24 months (lyophilised)

CoA

Available on Request

Frequently Asked Questions

How does GLP-RT differ from GLP-TZ?

Both GLP-RT and GLP-TZ activate GLP-1 and GIP receptors. GLP-RT additionally activates the glucagon receptor, creating a tri-agonist profile. Published data suggest this extra pathway contributes to greater body weight and metabolic effects in some study models versus dual agonism alone.

What reconstitution solvent is recommended?

Bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution solvent for research use, providing antimicrobial preservation for multi-use vials. Sterile water for injection may also be used for single-use applications.

Is a Certificate of Analysis available?

Yes. A Certificate of Analysis (CoA) documenting batch purity and specifications is available for every batch. Please contact us with your order number to request the relevant documentation.

What are the storage requirements?

Lyophilised GLP-RT should be stored at −20°C, protected from light and moisture. Once reconstituted, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles of reconstituted product.

GLP-RT — Retatrutide (Triple Agonist)